On 15th of October 2019, EuroEyes was successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited.
Morning trading volume almost equaled the shares sold by the German operator of eye clinics in the IPO, before the exercise of a greenshoe option, according to data compiled by Bloomberg. The stock pared some of the gains, up 59% in recent trading. EuroEyes raised $75.9 million selling shares last week at the midpoint of a marketed range.
Hamburg-based EuroEyes derived 63% of its 2018 revenue from Germany and another 28% from China. The company reported 43 million euro in sales last year, up 16% from 2017. In an interview with Bloomberg, Dr. Jørn Jørgensen, founder and CEO of EuroEyes, talks about the profitable IPO in Hong Kong and his expansion plans for the company.
About EuroEyes
The EuroEyes Clinic Group is a globally successful company that was founded 25 years ago in Hamburg and has its headquarters there until today. In addition to locations throughout Germany, EuroEyes is also represented in China and Denmark. The company offers patients the full range of refractive surgery for the correction of visual disorders. Using state-of-the-art eye laser and lens surgery procedures, EuroEyes treats more than 25,000 patients each year with myopia, farsightedness, astigmatism, presbyopia or cataract. The treatment enables the start of a life free of glasses and contact lenses without any impairment of visual quality.
Are you also interested in a treatment at EuroEyes or would you like to know more about us? Then feel free to contact our service or fill out our contact form. We are looking forward to seeing you at our clinic!
+49 40 348 09 29 0 – service center in Germany (English, German and Chinese)
Monday to Friday: 08:00 – 20:00
Saturday: 09:00 – 14:00
Join our Newsletter